PDCD1 and neoplasm: Nonetheless, the failure of anti-PD-1/PD-L1 immunotherapies to sustain a durable response in some melanoma patients emphasizes the need to delineate the tumor resistance mechanisms, characterize biomarkers for patient selection, and develop rational combinatorial therapeutic strategies.